miR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 47, 2012, Pages 19397-19402

  Jiang, Xi ^a   Huang, Hao ^a   Li, Zejuan ^a   He, Chunjiang ^a   Li, Yuanyuan ^a   Chen, Ping ^a   Gurbuxani, Sandeep ^a   Arnovitz, Stephen ^a   Hong, Gia Ming ^a   Price, Colles ^a   Ren, Haomin ^a   Kunjamma, Rejani B ^a   Neilly, Mary Beth ^a   Salat, Justin ^a   Wunderlich, Mark ^b   Slany, Robert K ^c   Zhang, Yanming ^d   Larson, Richard A ^a   Le Beau, Michelle M ^a   Mulloy, James C ^b   Rowley, Janet D ^a   Chen, Jianjun ^a   more..

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA 495; MIXED LINEAGE LEUKEMIA PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW TRANSPLANTATION; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTERNAL RIBOSOME ENTRY SITE; LEUKEMIA CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BASE SEQUENCE; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENE REARRANGEMENT; GENES, NEOPLASM; GENETIC ASSOCIATION STUDIES; HOMEODOMAIN PROTEINS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICRORNAS; MOLECULAR SEQUENCE DATA; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS;

EID: 84869835580     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1217519109     Document Type: Article

References (58)

1. Löwenberg B, Downing JR, Burnett A (1999) Acute myeloid leukemia. N Engl J Med 341(14):1051-1062.
2. Zhang Y, Rowley JD (2006) Chromatin structural elements and chromosomal translocations in leukemia. DNA Repair (Amst) 5(9-10):1282-1297.
3. Rowley JD (2001) Chromosome translocations: Dangerous liaisons revisited. Nat Rev Cancer 1(3):245-250.
4. Peterson LF, et al. (2007) Acute myeloid leukemia with the 8q22;21q22 translocation: Secondary mutational events and alternative t(8;21) transcripts. Blood 110(3):799-805.
5. Ziemin-van der Poel S, et al. (1991) Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci USA 88(23):10735-10739.
6. Tkachuk DC, Kohler S, Cleary ML (1992) Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 71(4):691-700.
7. Rowley JD (2008) Chromosomal translocations: Revisited yet again. Blood 112(6):2183-2189.
8. Chen J, Odenike O, Rowley JD (2010) Leukaemogenesis: more than mutant genes. Nat Rev Cancer 10(1):23-36.
9. Rowley JD, Olney HJ (2002) International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: Overview report. Genes Chromosomes Cancer 33(4):331-345.
10. Pui CH, et al. (2003) Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia 17(4):700-706.
11. Krivtsov AV, Armstrong SA (2007) MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 7(11):823-833.
12. Rowley JD (1998) Seminars from the University of Minnesota. Chromosome translocations: Dangerous liaisons. J Lab Clin Med 132(4):244-250.
13. Zeisig BB, et al. (2004) Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol 24(2):617-628.
14. Kroon E, et al. (1998) Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 17(13):3714-3725.
15. Smith LL, et al. (2011) Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells. Cell Stem Cell 8(6):649-662.
16. Wong P, Iwasaki M, Somervaille TC, So CW, Cleary ML (2007) Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev 21(21):2762-2774.
17. Kumar AR, et al. (2009) A role for MEIS1 in MLL-fusion gene leukemia. Blood 113(8):1756-1758.
18. Faber J, et al. (2009) HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 113(11):2375-2385.
19. Ayton PM, Cleary ML (2003) Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 17(18):2298-2307.
20. Roth JJ, Crist RC, Buchberg AM (2009) Might as well face it: MLL's addicted to HOX. Blood 113(11):2372-2373.
21. Orlovsky K, et al. (2011) Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation. Proc Natl Acad Sci USA 108(19):7956-7961.
22. Shah N, Sukumar S (2010) The Hox genes and their roles in oncogenesis. Nat Rev Cancer 10(5):361-371.
23. Milech N, Kees UR, Watt PM (2001) Novel alternative PBX3 isoforms in leukemia cells with distinct interaction specificities. Genes Chromosomes Cancer 32(3):275-280.
24. Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G (2001) Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol 21(1):224-234.
25. Armstrong SA, et al. (2002) MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30(1):41-47.
26. Bullinger L, et al. (2004) Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350(16):1605-1616.
27. Krivtsov AV, et al. (2006) Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442(7104):818-822.
28. Li Z, et al. (2009) Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias. Cancer Res 69(3):1109-1116.
29. Li Z, et al. (2012) Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood 119(10):2314-2324.
30. He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5(7):522-531.
31. Xiao C, Rajewsky K (2009) MicroRNA control in the immune system: Basic principles. Cell 136(1):26-36.
32. Li Z, et al. (2008) Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 105(40):15535-15540.
33. Mi S, et al. (2007) MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci USA 104(50):19971-19976.
34. Marcucci G, et al. (2008) MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 358(18):1919-1928.
35. Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Löwenberg B (2008) MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 111(10):5078-5085.
36. Garzon R, et al. (2008) Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 105(10):3945-3950.
37. Garzon R, et al. (2008) MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111(6):3183-3189.
38. Marcucci G, Mrózek K, Radmacher MD, Garzon R, Bloomfield CD (2011) The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 117(4):1121-1129.
39. Li Z, et al. (2012) miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun 3:688.
40. Arnold CP, et al. (2011) MicroRNA programs in normal and aberrant stem and progenitor cells. Genome Res 21(5):798-810.
41. Mi S, et al. (2010) Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc Natl Acad Sci USA 107(8):3710-3715.
42. Wong P, et al. (2010) The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res 70(9):3833-3842.
43. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98(9):5116-5121.
44. Super HJ, Martinez-Climent J, Rowley JD (1995) Molecular analysis of the Mono Mac 6 cell line: Detection of an MLL-AF9 fusion transcript. Blood 85(3):855-856.
45. Wei J, et al. (2008) Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell 13(6):483-495.
46. Mueller D, et al. (2009) Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol 7(11):e1000249.
47. He L, et al. (2005) A microRNA polycistron as a potential human oncogene. Nature 435(7043):828-833.
48. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545-15550.
49. Chang CP, et al. (1995) Pbx proteins display hexapeptide-dependent cooperative DNA binding with a subset of Hox proteins. Genes Dev 9(6):663-674.
50. Chang CP, Brocchieri L, Shen WF, Largman C, Cleary ML (1996) Pbx modulation of Hox homeodomain amino-terminal arms establishes different DNA-binding specificities across the Hox locus. Mol Cell Biol 16(4):1734-1745.
51. Hwang-Verslues WW, et al. (2011) miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene 30(21):2463-2474.
52. Li Z, et al. (2012) miR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3. Cancer Lett 323(1):41-47.
53. Xia ZB, Anderson M, Diaz MO, Zeleznik-Le NJ (2003) MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. Proc Natl Acad Sci USA 100(14):8342-8347.
54. Popovic R, et al. (2009) Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood 113(14):3314-3322.
55. Xiao C, et al. (2008) Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9(4):405-414.
56. Olive V, et al. (2009) miR-19 is a key oncogenic component of mir-17-92. Genes Dev 23(24):2839-2849.
57. Koralov SB, et al. (2008) Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 132(5):860-874.
58. He C, et al. (2012) Young intragenic miRNAs are less coexpressed with host genes than old ones: Implications of miRNA-host gene coevolution. Nucleic Acids Res 40(9):4002-4012.